Search

Your search keyword '"Catuogno, Silvia"' showing total 152 results
Start Over Author "Catuogno, Silvia"
152 results on '"Catuogno, Silvia"'

11. Selection of RNA aptamers targeting hypoxia in cancer

Author

Nuzzo, Silvia, primary, Iaboni, Margherita, additional, Ibba, Maria Luigia, additional, Rienzo, Anna, additional, Musumeci, Domenica, additional, Franzese, Monica, additional, Roscigno, Giuseppina, additional, Affinito, Alessandra, additional, Petrillo, Gianluca, additional, Quintavalle, Cristina, additional, Ciccone, Giuseppe, additional, Esposito, Carla Lucia, additional, and Catuogno, Silvia, additional

Published
2022
Full Text
View/download PDF

14. Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19

Author

Esposito, Carla L., primary, Van Roosbroeck, Katrien, additional, Santamaria, Gianluca, additional, Rotoli, Deborah, additional, Sandomenico, Annamaria, additional, Wierda, William G., additional, Ferrajoli, Alessandra, additional, Ruvo, Menotti, additional, Calin, George A., additional, de Franciscis, Vittorio, additional, and Catuogno, Silvia, additional

Published
2021
Full Text
View/download PDF

18. An Engineered RNA Platform to Neutralize DNMT1 Function and Control DNA Methylation for Myelodysplastic Syndrome

Author

Esposito, Carla Lucia, primary, Autiero, Ida, additional, Bassal, Mahmoud Adel, additional, Annamaria, Sandomenico, additional, Ummarino, Simone, additional, Borchiellini, Marta, additional, Ruvo, Menotti, additional, Catuogno, Silvia, additional, Ebralidze, Alexander, additional, De Franciscis, Vittorio, additional, and Di Ruscio, Annalisa, additional

Published
2020
Full Text
View/download PDF

28. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models

Author

Kanlikilicer, Pinar, primary, Ozpolat, Bulent, additional, Aslan, Burcu, additional, Bayraktar, Recep, additional, Gurbuz, Nilgun, additional, Rodriguez-Aguayo, Cristian, additional, Bayraktar, Emine, additional, Denizli, Merve, additional, Gonzalez-Villasana, Vianey, additional, Ivan, Cristina, additional, Lokesh, Ganesh L.R., additional, Amero, Paola, additional, Catuogno, Silvia, additional, Haemmerle, Monika, additional, Wu, Sherry Yen-Yao, additional, Mitra, Rahul, additional, Gorenstein, David G., additional, Volk, David E., additional, de Franciscis, Vittorio, additional, Sood, Anil K., additional, and Lopez-Berestein, Gabriel, additional

Published
2017
Full Text
View/download PDF

30. SERS-active metal-dielectric nanostructures integrated in microfluidic devices for label-free quantitative detection of miRNA

Author

Novara, Chiara, primary, Chiadò, Alessandro, additional, Paccotti, Niccolò, additional, Catuogno, Silvia, additional, Esposito, Carla Lucia, additional, Condorelli, Gerolama, additional, De Franciscis, Vittorio, additional, Geobaldo, Francesco, additional, Rivolo, Paola, additional, and Giorgis, Fabrizio, additional

Published
2017
Full Text
View/download PDF

33. Targeting Insulin Receptor with a Novel Internalizing Aptamer

Author

Iaboni, Margherita, primary, Fontanella, Raffaela, additional, Rienzo, Anna, additional, Capuozzo, Maria, additional, Nuzzo, Silvia, additional, Santamaria, Gianluca, additional, Catuogno, Silvia, additional, Condorelli, Gerolama, additional, de Franciscis, Vittorio, additional, and Esposito, Carla Lucia, additional

Published
2016
Full Text
View/download PDF

34. MiR-34c may protect lung cancer cells from paclitaxel-induced apoptosis

Author

Catuogno, Silvia

Abstract

MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that negatively regulate gene expression at post-transcriptional level in a sequence specific manner. They are involved in many biological processes, including cell proliferation, apoptosis and differentiation, and are considered as promising new therapeutic targets for cancer. However, the identity of miRNAs involved in apoptosis and their respective targets remain largely unknown. Given the elevated complexity of miRNA regulation of gene expression, we performed a functional screening as an alternative strategy to identify those miRNAs that in lung cancer cells may interfere with the apoptotic process. To this aim we generated a derivative of the non-small cell lung carcinoma A549 cell line in which caspase-8, a critical upstream initiator of apoptosis, can be activated by the administration of the small dimerizer drug AP20187. We found a number of miRNAs that may rescue cell viability from caspase-8 activation. They included miRNAs already described as oncogenic such as miR-17, miR-135, miR-520, but also some miRNAs such as miR-124-1 and miR-34c for which a tumor suppressive role has been instead described or expected. Among them, miR-34c-5p markedly increased resistance to paclitaxel induced apoptosis. We demonstrate that Bmf (Bcl-2 modifying factor) is a target of miR-34c-5p and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel via p53 downregulation.

Published
2011

36. Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy

Author

Esposito, Carla L, primary, Cerchia, Laura, additional, Catuogno, Silvia, additional, De Vita, Gennaro, additional, Dassie, Justin P, additional, Santamaria, Gianluca, additional, Swiderski, Piotr, additional, Condorelli, Gerolama, additional, Giangrande, Paloma H, additional, and de Franciscis, Vittorio, additional

Published
2014
Full Text
View/download PDF

41. Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay

Author

Bettazzi, Francesca, primary, Hamid-Asl, Ezat, additional, Esposito, Carla Lucia, additional, Quintavalle, Cristina, additional, Formisano, Nello, additional, Laschi, Serena, additional, Catuogno, Silvia, additional, Iaboni, Margherita, additional, Marrazza, Giovanna, additional, Mascini, Marco, additional, Cerchia, Laura, additional, De Franciscis, Vittorio, additional, Condorelli, Gerolama, additional, and Palchetti, Ilaria, additional

Published
2012
Full Text
View/download PDF

47. Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells.

Author

Esposito, Carla Lucia, Catuogno, Silvia, and de Franciscis, Vittorio

Subjects
*RNA interference, *GENE expression, *SMALL interfering RNA, *MICRORNA genetics, *OLIGONUCLEOTIDES
Abstract

RNA interference (RNAi) is an important biological process that ultimately leads to suppression of gene expression. Activators of RNAi are typically small interfering RNAs (siRNA) and microRNAs (miRNA) that offer considerable therapeutic potential. However, a major obstacle to take these these molecules to the clinic is the absence of safe and reliable means for their specific delivery to target cells. In this regard, a highly promising class of molecules is represented by nucleic acid aptamers. These are short, structured, single-stranded RNAs or DNAs oligonucleotides that, by binding with high specificity to target molecules, provide high affinity ligands and potential antagonists of disease-associated proteins. Further, because of the high binding specificity, aptamers represent a powerful tool for the selective delivery of therapeutic cargos, including mi/ siRNAs, chemotherapeutics, toxins and nanoparticles to cancer cells or tissues, thus potentially increasing the efficacy of a given therapy as well as reducing toxicity. In this review, we will focus on recent advances in the field of aptamer-mediated mi/siRNA delivery, discussing their potential and challenges in cancer therapy. [ABSTRACT FROM AUTHOR]

Published
2014

48. Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives

Author

Vittorio de Franciscis, Paola Ungaro, Gerolama Condorelli, Carla Lucia Esposito, Silvia Catuogno, Esposito, Carla Lucia, Catuogno, Silvia, Condorelli, Gerolama, Ungaro, Paola, and De Franciscis, Vittorio

Subjects
0301 basic medicine, lcsh:QH426-470, Chimera, Computer science, Aptamer, targeted delivery, aptamer, Computational biology, Review, lcsh:Genetics, 03 medical and health sciences, 030104 developmental biology, Genetic, Genetics, Nucleic acid, chimeras, Genetics (clinical)
Abstract

Nucleic acid-based aptamers have emerged as efficient delivery carriers of therapeutics. Thanks to their unique features, they can be, to date, considered one of the best targeting moieties, allowing the specific recognition of diseased cells and avoiding unwanted off-target effects on healthy tissues. In this review, we revise the most recent contributes on bispecific and multifunctional aptamer therapeutic chimeras. We will discuss key examples of aptamer-mediated delivery of nucleic acid and peptide-based therapeutics underlying their great potentiality and versatility. Achieved objectives and challenges will be highlighted as well.

Published
2018

49. STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma

Author

Silvia Nuzzo, Filomena de Nigris, Silvia Catuogno, Simona Romano, Carla Lucia Esposito, Vittorio de Franciscis, Esposito, Cl, Nuzzo, S, Catuogno, S, Romano, Simona, DE NIGRIS, Concetta, DE FRANCISCIS, Vittorio, Esposito, Carla Lucia, Nuzzo, Silvia, Catuogno, Silvia, de Nigris, Filomena, and de Franciscis, Vittorio

Subjects
0301 basic medicine, Angiogenesis, Aptamer, Article, Receptor tyrosine kinase, STAT3, 03 medical and health sciences, Chimera (genetics), RNA interference, Drug Discovery, Gene silencing, Viability assay, biology, Chemistry, lcsh:RM1-950, glioblastoma, targeted delivery, aptamer, lcsh:Therapeutics. Pharmacology, 030104 developmental biology, siRNA, Cancer research, biology.protein, Molecular Medicine
Abstract

Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults, and despite advances in neuro-oncology, the prognosis for patients remains dismal. The signal transducer and activator of transcription-3 (STAT3) has been reported as a key regulator of the highly aggressive mesenchymal GBM subtype, and its direct silencing (by RNAi oligonucleotides) has revealed a great potential as an anti-cancer therapy. However, clinical use of oligonucleotide-based therapies is dependent on safer ways for tissue-specific targeting and increased membrane penetration. The objective of this study is to explore the use of nucleic acid aptamers as carriers to specifically drive a STAT3 siRNA to GBM cells in a receptor-dependent manner. Using an aptamer that binds to and antagonizes the oncogenic receptor tyrosine kinase PDGFRβ (Gint4.T), here we describe the design of a novel aptamer-siRNA chimera (Gint4.T-STAT3) to target STAT3. We demonstrate the efficient delivery and silencing of STAT3 in PDGFRβ+GBM cells. Importantly, the conjugate reduces cell viability and migration in vitro and inhibits tumor growth and angiogenesis in vivo in a subcutaneous xenograft mouse model. Our data reveals Gint4.T-STAT3 conjugate as a novel molecule with great translational potential for GBM therapy. Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults, and despite advances in neuro-oncology, the prognosis for patients remains dismal. The signal transducer and activator of transcription-3 (STAT3) has been reported as a key regulator of the highly aggressive mesenchymal GBM subtype, and its direct silencing (by RNAi oligonucleotides) has revealed a great potential as an anti-cancer therapy. However, clinical use of oligonucleotide-based therapies is dependent on safer ways for tissue-specific targeting and increased membrane penetration. The objective of this study is to explore the use of nucleic acid aptamers as carriers to specifically drive a STAT3 siRNA to GBM cells in a receptor-dependent manner. Using an aptamer that binds to and antagonizes the oncogenic receptor tyrosine kinase PDGFRβ (Gint4.T), here we describe the design of a novel aptamer-siRNA chimera (Gint4.T-STAT3) to target STAT3. We demonstrate the efficient delivery and silencing of STAT3 in PDGFRβ+ GBM cells. Importantly, the conjugate reduces cell viability and migration in vitro and inhibits tumor growth and angiogenesis in vivo in a subcutaneous xenograft mouse model. Our data reveals Gint4.T-STAT3 conjugate as a novel molecule with great translational potential for GBM therapy.

Published
2018

50. SERS-active metal-dielectric nanostructures integrated in microfluidic devices for label-free quantitative detection of miRNA

Author

Vittorio de Franciscis, Gerolama Condorelli, Carla Lucia Esposito, Francesco Geobaldo, Fabrizio Giorgis, Chiara Novara, Silvia Catuogno, Niccolo' Paccotti, Alessandro Chiadò, Paola Rivolo, Novara, Chiara, Chiado, Alessandro, Paccotti, Niccolo, Catuogno, Silvia, Esposito, CARLA LUCIA, Condorelli, Gerolama, De Franciscis, Vittorio, Geobaldo, Francesco, Rivolo, Paola, and Giorgis, Fabrizio

Subjects
Materials science, Silver, Microfluidics, Metal Nanoparticles, Nanotechnology, 02 engineering and technology, 010402 general chemistry, Spectrum Analysis, Raman, 01 natural sciences, Silver nanoparticle, Nucleic acid thermodynamics, Limit of Detection, Cell Line, Tumor, Lab-On-A-Chip Devices, Humans, SERS-active, nanostructures, microfluidic, miRNA, Physical and Theoretical Chemistry, Detection limit, Oligonucleotide, Hybridization probe, Nucleic Acid Hybridization, 021001 nanoscience & nanotechnology, 0104 chemical sciences, Nanostructures, MicroRNAs, Membrane, 0210 nano-technology, Biosensor
Abstract

In this work, SERS-based microfluidic PDMS chips integrating silver-coated porous silicon membranes were used for the detection and quantitation of microRNAs (miRNAs), which consist of short regulatory non-coding RNA sequences typically over- or under-expressed in connection with several diseases such as oncogenesis. In detail, metal–dielectric nanostructures which provide noticeable Raman enhancements were functionalized according to a biological protocol, adapted and optimized from an enzyme-linked immunosorbent assay (ELISA), for the detection of miR-222. Two sets of experiments based on different approaches were designed and performed, yielding a critical comparison. In the first one, the labelled target miRNA is revealed through hybridization to a complementary thiolated DNA probe, immobilized on the silver nanoparticles. In the second one, the probe is halved into shorter strands (half1 and half2) that interact with the complementary miRNA in two steps of hybridization. Such an approach, taking advantage of the Raman labelling of half2, provides a label-free analysis of the target. After suitable optimisation of the procedures, two calibration curves allowing quantitative measurements were obtained and compared on the basis of the SERS maps acquired on the samples loaded with several miRNA concentrations. The selectivity of the two-step assay was confirmed by the detection of target miR-222 mixed with different synthetic oligos, simulating the hybridization interference coming from similar sequences in real biological samples. Finally, that protocol was applied to the analysis of miR-222 in cellular extracts using an optofluidic multichamber biosensor, confirming the potentialities of SERS-based microfluidics for early-cancer diagnosis.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results